Accupril and Pulmonary embolism - a phase IV clinical study of FDA data

Summary:

Pulmonary embolism is reported as a side effect among people who take Accupril (quinapril hydrochloride), especially for people who are female, 60+ old, have been taking the drug for 2 - 5 years also take Coumadin, and have Pain.

The phase IV clinical study analyzes which people have Pulmonary embolism when taking Accupril. It is created by eHealthMe based on reports of 13,164 people who have side effects when taking Accupril from the FDA, and is updated regularly.

What is Accupril?

Accupril has active ingredients of quinapril hydrochloride. It is often used in high blood pressure. eHealthMe is studying from 13,404 Accupril users. Check the latest studies of Accupril.

What is Pulmonary embolism?

Pulmonary embolism (blockage of the main artery of the lung) is found to be associated with 2,334 drugs and 2,959 conditions by eHealthMe. Check the latest studies of Pulmonary embolism.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

13,164 people reported to have side effects when taking Accupril.
Among them, 100 people (0.76%) have Pulmonary embolism.

Could Accupril cause Pulmonary embolism?

Among these 100 people:

How long have people been on Accupril when they have Pulmonary embolism? *

What is the gender of people who have Pulmonary embolism when taking Accupril? *

female: 65.66 %
male: 34.34 %

What is the age of people who have Pulmonary embolism when taking Accupril? *

What are other drugs people take besides Accupril? *

What are other side effects people have besides Pulmonary embolism? *

Pain: 39 people, 39.00%
Stress And Anxiety: 36 people, 36.00%
Osteoarthritis (a joint disease caused by cartilage loss in a joint): 33 people, 33.00%
Injury: 32 people, 32.00%
Gastritis (inflammation of stomach): 26 people, 26.00%
Weakness: 26 people, 26.00%
Deep Venous Thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis): 26 people, 26.00%
Confusional State: 26 people, 26.00%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 26 people, 26.00%
Diarrhea: 25 people, 25.00%

What are the existing conditions these people have? *

Pain: 19 people, 19.00%
Metastases To Bone (cancer spreads to bone): 18 people, 18.00%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 7 people, 7.00%
Diabetes: 7 people, 7.00%
Osteoarthritis (a joint disease caused by cartilage loss in a joint): 5 people, 5.00%
Pulmonary Hypertension (increase in blood pressure in the lung artery): 4 people, 4.00%
Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 4 people, 4.00%
High Blood Cholesterol: 2 people, 2.00%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 2 people, 2.00%
Bladder Cancer: 2 people, 2.00%

* Approximation only. Some reports may have incomplete information.

Do you take Accupril and have Pulmonary embolism?

- Check whether Pulmonary embolism is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Accupril:

Accupril (13,404 reports)

Browse all side effects of Accupril:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Pulmonary embolism:

Pulmonary embolism (2,334 drugs)

Browse all the conditions that are associated with Pulmonary embolism:

Pulmonary embolism (2,959 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on quinapril hydrochloride (the active ingredients of Accupril) and Accupril (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.